2023 Q4 Form 10-Q Financial Statement
#000149315223040626 Filed on November 13, 2023
Income Statement
Concept | 2023 Q4 | 2023 Q3 | 2022 Q3 |
---|---|---|---|
Revenue | $391.0K | $239.0K | $0.00 |
YoY Change | |||
Cost Of Revenue | $748.0K | $432.0K | $179.0K |
YoY Change | 1000.0% | 141.34% | |
Gross Profit | -$356.0K | -$193.0K | -$179.0K |
YoY Change | 423.53% | 7.82% | |
Gross Profit Margin | -91.05% | -80.75% | |
Selling, General & Admin | $9.768M | $10.21M | $7.990M |
YoY Change | 9.25% | 27.78% | 135.35% |
% of Gross Profit | |||
Research & Development | $6.838M | $7.130M | $4.452M |
YoY Change | 36.76% | 60.15% | 58.6% |
% of Gross Profit | |||
Depreciation & Amortization | $559.0K | $420.0K | $147.0K |
YoY Change | 118.36% | 185.71% | 98.33% |
% of Gross Profit | |||
Operating Expenses | $16.61M | $17.34M | $12.44M |
YoY Change | 19.12% | 39.38% | 100.65% |
Operating Profit | -$16.96M | -$17.54M | -$12.62M |
YoY Change | 21.08% | 38.94% | |
Interest Expense | $919.0K | $914.0K | -$265.0K |
YoY Change | 1897.83% | -444.91% | 65.63% |
% of Operating Profit | |||
Other Income/Expense, Net | -$294.0K | $88.00K | |
YoY Change | -239.34% | ||
Pretax Income | -$17.26M | -$17.43M | -$12.80M |
YoY Change | 25.06% | 36.19% | 47.26% |
Income Tax | $0.00 | ||
% Of Pretax Income | |||
Net Earnings | -$16.22M | -$16.22M | -$11.97M |
YoY Change | 27.25% | 35.53% | 37.71% |
Net Earnings / Revenue | -4148.34% | -6786.61% | |
Basic Earnings Per Share | -$0.50 | -$0.51 | -$0.40 |
Diluted Earnings Per Share | -$0.50 | -$0.51 | -$400.3K |
COMMON SHARES | |||
Basic Shares Outstanding | 31.97M shares | 31.71M shares | 29.89M shares |
Diluted Shares Outstanding | 32.46M shares | 31.80M shares | 29.90M shares |
Balance Sheet
Concept | 2023 Q4 | 2023 Q3 | 2022 Q3 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $31.26M | $38.64M | $62.45M |
YoY Change | -41.15% | -38.12% | 30.92% |
Cash & Equivalents | $7.971M | $13.18M | $29.83M |
Short-Term Investments | $23.29M | $25.46M | $32.62M |
Other Short-Term Assets | $6.349M | $6.490M | $11.51M |
YoY Change | -44.13% | -43.6% | 353.03% |
Inventory | $1.533M | $1.574M | $711.0K |
Prepaid Expenses | |||
Receivables | $294.0K | $205.0K | |
Other Receivables | $0.00 | $220.0K | |
Total Short-Term Assets | $39.44M | $47.13M | $75.08M |
YoY Change | -40.26% | -37.22% | 49.28% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $8.551M | $6.824M | $5.022M |
YoY Change | 135.95% | 35.88% | 57.28% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $213.0K | $224.0K | $205.0K |
YoY Change | 0.95% | 9.27% | -3.3% |
Total Long-Term Assets | $12.47M | $10.87M | $6.961M |
YoY Change | 57.0% | 56.17% | 85.08% |
TOTAL ASSETS | |||
Total Short-Term Assets | $39.44M | $47.13M | $75.08M |
Total Long-Term Assets | $12.47M | $10.87M | $6.961M |
Total Assets | $51.91M | $58.01M | $82.04M |
YoY Change | -29.81% | -29.3% | 51.77% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $3.220M | $3.292M | $2.006M |
YoY Change | 128.21% | 64.11% | -10.49% |
Accrued Expenses | $7.882M | $8.496M | $9.282M |
YoY Change | -19.38% | -8.47% | 104.9% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $310.0K |
YoY Change | -100.0% | -100.0% | 121.43% |
Long-Term Debt Due | $130.0K | $280.0K | |
YoY Change | |||
Total Short-Term Liabilities | $11.64M | $12.45M | $11.60M |
YoY Change | 0.38% | 7.38% | 67.8% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $14.38M | $14.04M | $200.0K |
YoY Change | 10171.43% | 6920.0% | -95.59% |
Other Long-Term Liabilities | $6.589M | ||
YoY Change | 291.27% | ||
Total Long-Term Liabilities | $0.00 | $0.00 | $6.789M |
YoY Change | -100.0% | -100.0% | 9.1% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $11.64M | $12.45M | $11.60M |
Total Long-Term Liabilities | $0.00 | $0.00 | $6.789M |
Total Liabilities | $28.44M | $29.17M | $23.23M |
YoY Change | 53.57% | 25.56% | 76.89% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$226.0M | -$209.8M | |
YoY Change | 41.87% | ||
Common Stock | $4.000K | $3.000K | |
YoY Change | 33.33% | ||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | $25.00K | $25.00K | |
YoY Change | 0.0% | ||
Treasury Stock Shares | |||
Shareholders Equity | $20.81M | $25.75M | $58.81M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $51.91M | $58.01M | $82.04M |
YoY Change | -29.81% | -29.3% | 51.77% |
Cashflow Statement
Concept | 2023 Q4 | 2023 Q3 | 2022 Q3 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$16.22M | -$16.22M | -$11.97M |
YoY Change | 27.25% | 35.53% | 37.71% |
Depreciation, Depletion And Amortization | $559.0K | $420.0K | $147.0K |
YoY Change | 118.36% | 185.71% | 98.33% |
Cash From Operating Activities | -$13.82M | -$14.32M | -$9.220M |
YoY Change | 62.39% | 55.31% | 85.15% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $1.334M | $1.680M | -$963.0K |
YoY Change | 110.41% | -274.45% | 62.69% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $2.186M | -$80.00K | -$32.61M |
YoY Change | -56.47% | -99.75% | 44568.49% |
Cash From Investing Activities | $852.0K | -$1.770M | -$33.57M |
YoY Change | -80.58% | -94.73% | 4948.73% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 5.234M | 470.0K | 133.0K |
YoY Change | -1788.39% | 253.38% | -99.1% |
NET CHANGE | |||
Cash From Operating Activities | -13.82M | -14.32M | -9.220M |
Cash From Investing Activities | 852.0K | -1.770M | -33.57M |
Cash From Financing Activities | 5.234M | 470.0K | 133.0K |
Net Change In Cash | -7.733M | -15.62M | -42.66M |
YoY Change | 74.48% | -63.38% | -567.86% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$13.82M | -$14.32M | -$9.220M |
Capital Expenditures | $1.334M | $1.680M | -$963.0K |
Free Cash Flow | -$15.15M | -$16.00M | -$8.257M |
YoY Change | 65.72% | 93.77% | 88.18% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--03-31 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2024 | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001641631 | ||
CY2023Q1 | XAIR |
Bifurcated Derivative
BifurcatedDerivative
|
usd | |
XAIR |
Dividend Income Loss Operating
DividendIncomeLossOperating
|
usd | ||
CY2022Q3 | XAIR |
Estimated Liability For Contingent Loss
EstimatedLiabilityForContingentLoss
|
usd | |
XAIR |
Estimated Liability For Contingent Loss
EstimatedLiabilityForContingentLoss
|
usd | ||
CY2023Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
usd | |
CY2023Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
usd | |
CY2022Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
usd | |
CY2022Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
usd | |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
usd | ||
XAIR |
Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
|
usd | ||
XAIR |
Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
|
usd | ||
us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
usd | ||
us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
usd | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
usd | ||
us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
usd | ||
XAIR |
Payment For Proceeds From Sale And Maturity Of Marketable Securities
PaymentForProceedsFromSaleAndMaturityOfMarketableSecurities
|
usd | ||
XAIR |
Payments To Security Deposits Made On Operating Leases
PaymentsToSecurityDepositsMadeOnOperatingLeases
|
usd | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
usd | ||
us-gaap |
Proceeds From Bank Debt
ProceedsFromBankDebt
|
usd | ||
XAIR |
Debt Discount
DebtDiscount
|
usd | ||
XAIR |
End Of Term Loan Liability
EndOfTermLoanLiability
|
usd | ||
XAIR |
Warrant Liabilities
WarrantLiabilities
|
usd | ||
XAIR |
Derivatives Liability
DerivativesLiability
|
usd | ||
XAIR |
Rightofuse Assets
RightofuseAssets
|
usd | ||
XAIR |
Operating Lease Liabilities
OperatingLeaseLiabilities
|
usd | ||
us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
usd | ||
CY2023Q1 | us-gaap |
Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
|
usd | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
|
shares | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
|
|||
CY2023Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
|
usd | |
CY2023Q1 | XAIR |
Goods Received Not Invoiced
GoodsReceivedNotInvoiced
|
usd | |
CY2023Q3 | XAIR |
Accrued Circassia Settlement Long Term
AccruedCircassiaSettlementLongTerm
|
usd | |
CY2023Q3 | us-gaap |
Other Long Term Debt
OtherLongTermDebt
|
usd | |
us-gaap |
Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
|
shares | ||
CY2023Q2 | XAIR |
Amortization Of Debt Discount
AmortizationOfDebtDiscount
|
usd | |
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-09-30 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
001-38892 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
BEYOND AIR, INC. | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
47-3812456 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
900 Stewart Avenue | ||
dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 301 | ||
CY2023Q3 | us-gaap |
Loans Payable Current
LoansPayableCurrent
|
275000 | usd |
CY2023Q1 | us-gaap |
Loans Payable Current
LoansPayableCurrent
|
775000 | usd |
CY2023Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
12454000 | usd |
CY2023Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
19780000 | usd |
CY2023Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
2087000 | usd |
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Garden City | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
NY | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
11530 | ||
dei |
City Area Code
CityAreaCode
|
516 | ||
dei |
Local Phone Number
LocalPhoneNumber
|
665-8200 | ||
dei |
Security12b Title
Security12bTitle
|
Common Stock, par value $0.0001 per share | ||
dei |
Trading Symbol
TradingSymbol
|
XAIR | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2023Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
31972434 | shares |
CY2023Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
13179000 | usd |
CY2023Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
29158000 | usd |
CY2023Q3 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
25463000 | usd |
CY2023Q1 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
16724000 | usd |
CY2023Q3 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
5231000 | usd |
CY2023Q1 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
10129000 | usd |
CY2023Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
205000 | usd |
CY2023Q3 | us-gaap |
Inventory Net
InventoryNet
|
1574000 | usd |
CY2023Q1 | us-gaap |
Inventory Net
InventoryNet
|
1129000 | usd |
CY2023Q1 | us-gaap |
Grants Receivable
GrantsReceivable
|
420000 | usd |
CY2023Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1481000 | usd |
CY2023Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1850000 | usd |
CY2023Q3 | us-gaap |
Assets Current
AssetsCurrent
|
47134000 | usd |
CY2023Q1 | us-gaap |
Assets Current
AssetsCurrent
|
59410000 | usd |
CY2023Q3 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
1529000 | usd |
CY2023Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
1632000 | usd |
CY2023Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
2294000 | usd |
CY2023Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
2493000 | usd |
CY2023Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
6824000 | usd |
CY2023Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
5003000 | usd |
CY2023Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
224000 | usd |
CY2023Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
212000 | usd |
CY2023Q3 | us-gaap |
Assets
Assets
|
58005000 | usd |
CY2023Q1 | us-gaap |
Assets
Assets
|
68749000 | usd |
CY2023Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3292000 | usd |
CY2023Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2016000 | usd |
CY2023Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
8496000 | usd |
CY2023Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
16613000 | usd |
CY2023Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
391000 | usd |
CY2023Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
376000 | usd |
CY2023Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
2321000 | usd |
CY2023Q3 | us-gaap |
Long Term Loans Payable
LongTermLoansPayable
|
14044000 | usd |
CY2023Q1 | us-gaap |
Long Term Loans Payable
LongTermLoansPayable
|
120000 | usd |
CY2023Q3 | XAIR |
Warrant Liability
WarrantLiability
|
238000 | usd |
CY2023Q3 | XAIR |
Bifurcated Derivative
BifurcatedDerivative
|
349000 | usd |
CY2023Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
4500000 | usd |
CY2023Q3 | us-gaap |
Liabilities
Liabilities
|
29173000 | usd |
CY2023Q1 | us-gaap |
Liabilities
Liabilities
|
26721000 | usd |
CY2023Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
CY2023Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
CY2023Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2023Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2023Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2023Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2023Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2023Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2023Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
31972434 | shares |
CY2023Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
31972434 | shares |
CY2023Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
30738585 | shares |
CY2023Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
30738585 | shares |
CY2023Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
3000 | usd |
CY2023Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
3000 | usd |
CY2023Q3 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
25000 | usd |
CY2023Q1 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
25000 | usd |
CY2023Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
235495000 | usd |
CY2023Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
217339000 | usd |
CY2023Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-209770000 | usd |
CY2023Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-179455000 | usd |
CY2023Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
43000 | usd |
CY2023Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
53000 | usd |
CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
25746000 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
37915000 | usd |
CY2023Q3 | us-gaap |
Minority Interest
MinorityInterest
|
3085000 | usd |
CY2023Q1 | us-gaap |
Minority Interest
MinorityInterest
|
4113000 | usd |
CY2023Q3 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
28831000 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
42028000 | usd |
CY2023Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
58005000 | usd |
CY2023Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
68749000 | usd |
CY2023Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
239000 | usd |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
298000 | usd | |
CY2023Q3 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
432000 | usd |
CY2022Q3 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
179000 | usd |
us-gaap |
Cost Of Revenue
CostOfRevenue
|
735000 | usd | |
us-gaap |
Cost Of Revenue
CostOfRevenue
|
179000 | usd | |
CY2023Q3 | us-gaap |
Gross Profit
GrossProfit
|
-193000 | usd |
CY2022Q3 | us-gaap |
Gross Profit
GrossProfit
|
-179000 | usd |
us-gaap |
Gross Profit
GrossProfit
|
-437000 | usd | |
us-gaap |
Gross Profit
GrossProfit
|
-179000 | usd | |
CY2023Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
7130000 | usd |
CY2022Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4452000 | usd |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
11826000 | usd | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
7678000 | usd | |
CY2023Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
10211000 | usd |
CY2022Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7990000 | usd |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
21147000 | usd | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
16203000 | usd | |
CY2023Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
17342000 | usd |
CY2022Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
12442000 | usd |
us-gaap |
Operating Expenses
OperatingExpenses
|
32972000 | usd | |
us-gaap |
Operating Expenses
OperatingExpenses
|
23882000 | usd | |
CY2023Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-17535000 | usd |
CY2022Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-12621000 | usd |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-33410000 | usd | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-24061000 | usd | |
CY2023Q3 | XAIR |
Dividend Income Loss Operating
DividendIncomeLossOperating
|
641000 | usd |
XAIR |
Dividend Income Loss Operating
DividendIncomeLossOperating
|
1050000 | usd | |
CY2023Q3 | us-gaap |
Interest Expense
InterestExpense
|
914000 | usd |
CY2022Q3 | us-gaap |
Interest Expense
InterestExpense
|
48000 | usd |
us-gaap |
Interest Expense
InterestExpense
|
1072000 | usd | |
us-gaap |
Interest Expense
InterestExpense
|
96000 | usd | |
CY2023Q3 | XAIR |
Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
|
324000 | usd |
XAIR |
Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
|
647000 | usd | |
CY2023Q3 | XAIR |
Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
|
500000 | usd |
XAIR |
Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
|
1012000 | usd | |
CY2023Q3 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-42000 | usd |
CY2022Q3 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-217000 | usd |
us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-34000 | usd | |
us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-394000 | usd | |
CY2023Q3 | XAIR |
Estimated Liability For Contingent Loss
EstimatedLiabilityForContingentLoss
|
-400000 | usd |
XAIR |
Estimated Liability For Contingent Loss
EstimatedLiabilityForContingentLoss
|
-598000 | usd | |
CY2022Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
88000 | usd |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-77000 | usd | |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
99000 | usd | |
CY2023Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
109000 | usd |
CY2022Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-177000 | usd |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
929000 | usd | |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-391000 | usd | |
CY2023Q3 | us-gaap |
Profit Loss
ProfitLoss
|
-17426000 | usd |
CY2022Q3 | us-gaap |
Profit Loss
ProfitLoss
|
-12797000 | usd |
us-gaap |
Profit Loss
ProfitLoss
|
-32481000 | usd | |
us-gaap |
Profit Loss
ProfitLoss
|
-24452000 | usd | |
CY2023Q3 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-1205000 | usd |
CY2022Q3 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-830000 | usd |
us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-2165000 | usd | |
us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-1550000 | usd | |
CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16220000 | usd |
CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11968000 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-30315000 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-22902000 | usd | |
CY2023Q3 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
-35000 | usd |
CY2022Q3 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
171000 | usd |
us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
-9000 | usd | |
us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
343000 | usd | |
CY2023Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-16255000 | usd |
CY2022Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-11797000 | usd |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-30325000 | usd | |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-22559000 | usd | |
CY2023Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.51 | |
CY2023Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.51 | |
CY2022Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.40 | |
CY2022Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.40 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.96 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.96 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.77 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.77 | ||
CY2023Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
31800492 | shares |
CY2023Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
31800492 | shares |
CY2022Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
29898825 | shares |
CY2022Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
29898825 | shares |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
31592880 | shares | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
31592880 | shares | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
29893414 | shares | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
29893414 | shares | |
CY2023Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
42028000 | usd |
CY2023Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
217000 | usd |
CY2023Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
5813000 | usd |
CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
6115000 | usd |
CY2023Q2 | us-gaap |
Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
|
25000 | usd |
CY2023Q2 | us-gaap |
Profit Loss
ProfitLoss
|
-15055000 | usd |
CY2023Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
39143000 | usd |
CY2023Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
39143000 | usd |
CY2023Q3 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
688000 | usd |
CY2023Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
6460000 | usd |
CY2023Q3 | us-gaap |
Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
|
-35000 | usd |
CY2023Q3 | us-gaap |
Profit Loss
ProfitLoss
|
-17426000 | usd |
CY2023Q3 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
28831000 | usd |
CY2022Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
78209000 | usd |
CY2022Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4624000 | usd |
CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
|
172000 | usd |
CY2022Q2 | us-gaap |
Profit Loss
ProfitLoss
|
-11654000 | usd |
CY2022Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
71351000 | usd |
CY2022Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
71351000 | usd |
CY2022Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
71351000 | usd |
CY2022Q3 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
214000 | usd |
CY2022Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4714000 | usd |
CY2022Q3 | us-gaap |
Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
|
171000 | usd |
CY2022Q3 | us-gaap |
Profit Loss
ProfitLoss
|
-12797000 | usd |
CY2022Q3 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
63652000 | usd |
CY2022Q3 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
63652000 | usd |
us-gaap |
Profit Loss
ProfitLoss
|
-32481000 | usd | |
us-gaap |
Profit Loss
ProfitLoss
|
-24452000 | usd | |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
682000 | usd | |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
235000 | usd | |
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
102000 | usd | |
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
102000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
12575000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9338000 | usd | |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
413000 | usd | |
XAIR |
Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
|
647000 | usd | |
XAIR |
Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
|
1012000 | usd | |
us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
175000 | usd | |
us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
138000 | usd | |
XAIR |
Foreign Currency Adjustments
ForeignCurrencyAdjustments
|
1000 | usd | |
XAIR |
Foreign Currency Adjustments
ForeignCurrencyAdjustments
|
394000 | usd | |
us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
235000 | usd | |
us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-105000 | usd | |
us-gaap |
Provision For Other Losses
ProvisionForOtherLosses
|
61000 | usd | |
us-gaap |
Provision For Other Losses
ProvisionForOtherLosses
|
49000 | usd | |
XAIR |
Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
|
-420000 | usd | |
XAIR |
Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
|
-87000 | usd | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
505000 | usd | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
363000 | usd | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
205000 | usd | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-367000 | usd | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-421000 | usd | |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1277000 | usd | |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
864000 | usd | |
us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
-12605000 | usd | |
us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
-3108000 | usd | |
us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-194000 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-31472000 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-16059000 | usd | |
XAIR |
Proceed From Payments To Acquire Marketable Securities
ProceedFromPaymentsToAcquireMarketableSecurities
|
55213000 | usd | |
XAIR |
Proceed From Payments To Acquire Marketable Securities
ProceedFromPaymentsToAcquireMarketableSecurities
|
32617000 | usd | |
XAIR |
Payment For Proceeds From Sale And Maturity Of Marketable Securities
PaymentForProceedsFromSaleAndMaturityOfMarketableSecurities
|
-46269000 | usd | |
XAIR |
Payments To Security Deposits Made On Operating Leases
PaymentsToSecurityDepositsMadeOnOperatingLeases
|
-2000 | usd | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2477000 | usd | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1221000 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-11421000 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-33835000 | usd | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
6501000 | usd | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
214000 | usd | |
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
217000 | usd | |
us-gaap |
Proceeds From Bank Debt
ProceedsFromBankDebt
|
15817000 | usd | |
us-gaap |
Repayments Of Bank Debt
RepaymentsOfBankDebt
|
500000 | usd | |
us-gaap |
Repayments Of Bank Debt
RepaymentsOfBankDebt
|
617000 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
22036000 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-403000 | usd | |
us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-19000 | usd | |
us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
2000 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-20876000 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-50296000 | usd | |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
39287000 | usd |
CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
90230000 | usd |
CY2023Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
18410000 | usd |
CY2022Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
39934000 | usd |
XAIR |
Debt Discount
DebtDiscount
|
4541000 | usd | |
XAIR |
End Of Term Loan Liability
EndOfTermLoanLiability
|
-613000 | usd | |
XAIR |
Warrant Liabilities
WarrantLiabilities
|
885000 | usd | |
XAIR |
Derivatives Liability
DerivativesLiability
|
-1361000 | usd | |
XAIR |
Rightofuse Assets
RightofuseAssets
|
274000 | usd | |
XAIR |
Operating Lease Liabilities
OperatingLeaseLiabilities
|
274000 | usd | |
us-gaap |
Interest Paid Net
InterestPaidNet
|
369000 | usd | |
us-gaap |
Interest Paid Net
InterestPaidNet
|
16000 | usd | |
us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
64000 | usd | |
CY2023Q1 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
16724000 | usd |
us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<p id="xdx_844_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zOOAy0fS8599" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zGNI5VbHw5U6">Reclassifications</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on the reported results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | ||
us-gaap |
Use Of Estimates
UseOfEstimates
|
<p id="xdx_848_eus-gaap--UseOfEstimates_zgxUNgUSUHKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zoQ8zGtgJGIl">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its significant estimates including accruals for expenses under consulting, licensing agreements, and clinical trials, stock-based compensation, contingency recognition and the determination of deferred tax attributes and the valuation allowance thereon.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-31500000 | usd | |
CY2023Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-209800000 | usd |
CY2023Q3 | XAIR |
Cash And Cash Equivalents And Marketable Securities
CashAndCashEquivalentsAndMarketableSecurities
|
38600000 | usd |
CY2023Q3 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
25463000 | usd |
CY2023Q3 | us-gaap |
Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
|
588000 | usd |
CY2023Q1 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
16724000 | usd |
CY2023Q3 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
43874000 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
56011000 | usd |
XAIR |
Warrants Liability
WarrantsLiability
|
885000 | usd | |
XAIR |
Derivative Liability
DerivativeLiability
|
1361000 | usd | |
XAIR |
Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
|
647000 | usd | |
XAIR |
Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
|
1012000 | usd | |
CY2023Q3 | XAIR |
Warrant Liability
WarrantLiability
|
238000 | usd |
CY2023Q3 | XAIR |
Bifurcated Derivative
BifurcatedDerivative
|
349000 | usd |
XAIR |
Decline In Restricted Cash
DeclineInRestrictedCash
|
4900000 | usd | |
XAIR |
Incremental Amount
IncrementalAmount
|
2500000 | usd | |
CY2023Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
13179000 | usd |
CY2023Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
29158000 | usd |
CY2023Q3 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
5231000 | usd |
CY2023Q1 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
10129000 | usd |
CY2023Q3 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
18410000 | usd |
CY2023Q1 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
39287000 | usd |
CY2023Q3 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
25463000 | usd |
CY2023Q3 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
25463000 | usd |
us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-105000 | usd | |
CY2023Q3 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
0 | usd |
us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zM9bgmrxzDCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zQE4ZQC6oiM5">Supplier Concentration</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company relies on third-party suppliers to provide materials for its devices and consumables.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the three months ended September 30, 2023, the Company purchased approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoThirdPartyVendorsMember_zHUjU6jrqUQd" title="Concentration risk percentage">88</span>% of its materials from two third-party vendors, with these vendors representing <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorOneMember_zvWZihIL25zb" title="Concentration risk percentage">80</span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorTwoMember_zyKc7cwRr2L5" title="Concentration risk percentage">8</span>%, respectively. In the three months ended September 30, 2022, the Company purchased approximately <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoThirdPartyVendorsMember_zvnJSheVs80k" title="Concentration risk percentage">80</span>% of its materials from two third-party vendors, with these vendors representing <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorOneMember_zOeH3WVqX6Jg" title="Concentration risk percentage">59</span>% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorTwoMember_z5hCc4wzm9zh" title="Concentration risk percentage">21</span>%, respectively. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the six months ended September 30, 2023, the Company purchased approximately <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoThirdPartyVendorsMember_zZhkYrfx5Dyb" title="Concentration risk percentage">86</span>% of its materials from two third-party vendors, with these vendors representing <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorOneMember_zyZdh01FpCxa" title="Concentration risk percentage">73</span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorTwoMember_z6SUivkmRUj1" title="Concentration risk percentage">13</span>%, respectively. In the six months ended September 30, 2022, the Company purchased approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoThirdPartyVendorsMember_zPlk9vghfRx8" title="Concentration risk percentage">69</span>% of its materials from two third-party vendors, with these vendors representing <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorOneMember_zlib8aHUsBtd" title="Concentration risk percentage">53</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdPartyVendorTwoMember_zmmXFkXGrwm7" title="Concentration risk percentage">16</span>%, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> | ||
CY2023Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
8733000 | usd |
CY2023Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
6256000 | usd |
CY2023Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1909000 | usd |
CY2023Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1254000 | usd |
CY2023Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
6824000 | usd |
CY2023Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
5003000 | usd |
CY2023Q3 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
400000 | usd |
CY2022Q3 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
100000 | usd |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
700000 | usd | |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
200000 | usd | |
us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
200000 | usd | |
us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
42500 | shares | |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
1101100 | shares |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
6.78 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
|
1000 | shares | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
5.65 | ||
CY2023Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
258000 | usd |
CY2023Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
184000 | usd |
CY2023Q3 | XAIR |
Total Shortterm Accrued Expense
TotalShorttermAccruedExpense
|
8496000 | usd |
CY2023Q1 | XAIR |
Total Shortterm Accrued Expense
TotalShorttermAccruedExpense
|
16613000 | usd |
CY2023Q1 | XAIR |
Accrued Circassia Settlement Long Term
AccruedCircassiaSettlementLongTerm
|
4500000 | usd |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
|
6800 | shares | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
|
5.06 | ||
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
1095300 | shares |
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
6.79 | |
CY2023Q3 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
700000 | usd |
CY2022Q3 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
700000 | usd |
us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
1500000 | usd | |
us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
1400000 | usd | |
XAIR |
Unrecognized Compensation Cost
UnrecognizedCompensationCost
|
3600000 | usd | |
us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P1Y7M6D | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y3M | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y3M | ||
CY2023Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
6460000 | usd |
CY2022Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4714000 | usd |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
12575000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9338000 | usd | |
CY2023Q3 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
694363 | shares |
CY2023Q3 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
6.02 | |
CY2023Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1481000 | usd |
CY2023Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1850000 | usd |
CY2023Q3 | XAIR |
Vendors Research And Development
VendorsResearchAndDevelopment
|
1180000 | usd |
CY2023Q1 | XAIR |
Vendors Research And Development
VendorsResearchAndDevelopment
|
426000 | usd |
CY2023Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
581000 | usd |
CY2023Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1221000 | usd |
CY2023Q3 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
1397000 | usd |
CY2023Q1 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
985000 | usd |
CY2023Q3 | XAIR |
Contingent Litigation And Settlements
ContingentLitigationAndSettlements
|
400000 | usd |
CY2023Q1 | XAIR |
Contingent Litigation And Settlements
ContingentLitigationAndSettlements
|
10298000 | usd |
CY2023Q3 | XAIR |
Circassia Settlement Current
CircassiaSettlementCurrent
|
4500000 | usd |
CY2023Q1 | XAIR |
Circassia Settlement Current
CircassiaSettlementCurrent
|
3500000 | usd |
CY2023Q3 | XAIR |
Goods Received Not Invoiced
GoodsReceivedNotInvoiced
|
180000 | usd |
CY2023Q1 | us-gaap |
Other Long Term Debt
OtherLongTermDebt
|
4500000 | usd |
us-gaap |
Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
|
392465 | shares | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
10310154 | shares | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6991751 | shares | |
CY2022Q3 | us-gaap |
Loss Contingency Accrual Payments
LossContingencyAccrualPayments
|
2500000 | usd |
CY2023Q3 | us-gaap |
Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
|
4500000 | usd |
CY2023Q1 | us-gaap |
Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
|
8000000.0 | usd |
CY2023Q2 | us-gaap |
Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
|
7600000 | usd |
CY2023Q2 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
233843 | shares |
CY2023Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
5.88 | |
CY2023Q2 | us-gaap |
Proceeds From Interest Received
ProceedsFromInterestReceived
|
15800000 | usd |
CY2023Q3 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
|
1750000 | usd |
CY2023Q3 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
7000000 | usd |
CY2023Q3 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
7000000 | usd |
CY2023Q3 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
|
1750000 | usd |
CY2023Q3 | us-gaap |
Long Term Debt
LongTermDebt
|
17500000 | usd |
CY2023Q3 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
17500000 | usd |
CY2023Q2 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
17500000 | usd |
CY2023Q3 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
4541000 | usd |
CY2023Q2 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
4541000 | usd |
CY2023Q3 | XAIR |
Amortization Of Debt Discount
AmortizationOfDebtDiscount
|
413000 | usd |
CY2023Q3 | XAIR |
Final Payment Liability
FinalPaymentLiability
|
613000 | usd |
CY2023Q2 | XAIR |
Final Payment Liability
FinalPaymentLiability
|
613000 | usd |
CY2023Q3 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
13985000 | usd |
CY2023Q2 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
13572000 | usd |